DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the INNOVA CAPTAB LIMITED (INNOVACAP) share price today?

INNOVA CAPTAB LIMITED (INNOVACAP) is trading at ₹962.7 on the NSE, down 4.81% on the day. Source: DocStoX.

What is the PE ratio of INNOVA CAPTAB LIMITED?

INNOVA CAPTAB LIMITED has a price-to-earnings (PE) ratio of 39.1 in the Healthcare sector.

What is the market capitalisation of INNOVA CAPTAB LIMITED?

INNOVA CAPTAB LIMITED has a market capitalisation of approximately ₹5,531 crore.

INNOVA CAPTAB LIMITED

INNOVACAP·NSE·Healthcare

₹962.70▼ -48.60 (-4.81%)

Healthcare · Pharmaceuticals

Revenue compounding 21% a year

Day₹957.10

₹1019.70

52W₹622

₹103583%

Open

₹1018.00

High

₹1019.70

Low

₹957.10

Prev Close

₹1011.30

Volume

58.4K

VWAP

₹971.86

Snapshot

Key fundamentals

Market Cap

₹5,531 Cr

P/E Ratio

39.09Expensive

P/B Ratio

5.13

EPS

₹24.63

Book Value

₹191.00

ROE

13.70%Average

ROCE

15.00%Decent

Dividend Yield

0.20%

Debt / Equity

0.32Moderate

Face Value

₹10.00

52W High

₹1034.85

52W Low

₹622.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹222

▼ 76.9%downside

Trading at ₹963 — 77% above our estimate

BearFair valueBull

₹189₹222₹325

/100

Business quality — Solid

Growth 91Profitability 40Efficiency 18Valuation 56

Plain English

Our view

Revenue compounding 21% a year
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Revenue compounding 21% over 3 years
Profit growing 28% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

14% ROE fading to 13% over ~3 yrs, on ₹191 book

₹194

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹325

Analyst target

No analyst coverage

—

Blended fair value₹222

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 21% over 3 years
Profit growing 28% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

39.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

13.7%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.32Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹5,531 Cr

P/B

5.13

EPS

₹24.63

Div Yield

0.20%

What changed

Recent changes

Foreign investors+0.1% stake last quarter
Domestic institutions-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 39.1×

Growth

Strong

+21% rev CAGR

Profitability

Healthy

13.7% ROE

Financial health

Comfortable

D/E 0.32

Momentum

N/A

No technicals

Today

Trading activity

Delivery %50.0%

Turnover₹567.27L Cr

Trades5,783

VWAP₹971.86

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+20.7%

+31.7%

10Y

—

Profit

+27.5%

+32.9%

10Y

—

EPS

+20.3%

-38.8%

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 32.5% CAGR over last 5 years

Watch-outs

Cons

Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.11 pts; domestic institutions reduced 0.22 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

51%

Promoter

Promoters

50.9%0.00

Public

28.8%+0.10

FII / FPI

0.3%+0.11

DII

19.9%-0.22

Total shareholders

35,881-1,084 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter50.90%

FII0.34%

DII19.92%

Public28.84%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]